Innovative Drug Discovery Model
At MD Anderson, we work under the same roof as world-class physicians and researchers, providing unparalleled insights that guide each of our programs. We learn from those we treat, starting with a patient and their cancer in order to drive new therapeutics based on specific unmet needs.
To discover and develop effective new therapies, we have created state-of-the-art research platforms with industry-scale capabilities and collaborative teams of experts driven toward a singular goal: improving the lives of our patients.
Therapeutics Discovery Research Platforms
Collaborative Agreements
Our collaborative agreements with leading pharmaceutical and biotechnology companies also are critical to our mission of advancing impactful therapies. These agreements can take a variety of forms based on how best to meet the needs of our patients.
Strategic Alliances
By aligning with leading biopharmaceutical companies and strategic investors, we are able to combine the unique infrastructure and drug development capabilities of Therapeutics Discovery with the novel therapeutics and expertise of our collaborators to accelerate new therapies to benefit patients.
-
Astellas
Agreement to research and develop new treatments for patients with acute myeloid leukemia
-
Blueprint Medicines
Research collaboration to accelerate development of CDK2 targeted therapy
-
Boehringer Ingelheim
Collaboration to accelerate development of therapies targeting KRAS and TRAILR2
-
Denali Therapeutics
Research collaboration with NDC to develop novel therapies for Alzheimer’s and other neurodegenerative diseases
-
Eisbach Bio
Strategic collaboration to develop medicines targeting epigenetic machinery in oncology
-
Ionis
Research collaboration using Ionis’ antisense technology and MD Anderson's expertise to develop novel cancer therapies
-
Obsidian Therapeutics
Multi-year strategic collaboration to expedite research and development of novel engineered TILs for solid tumors
-
Orionis Biosciences
Research collaboration to unlock drug development opportunities through genome-scale mapping of drug-target interactions
-
Refuge Biotechnologies
Strategic collaboration to advance new cell therapies for solid tumors
-
Schrodinger
Research collaboration focused on accelerating and optimizing the development of WEE1 inhibitor program
-
Taiho Oncology
Collaboration to conduct preclinical development and clinical evaluation of novel medicines to treat brain metastases
-
Takeda
Exclusive license and research agreement to develop off-the-shelf CAR NK cell therapy platform
-
XENCOR
Strategic research collaboration and commercialization agreement to develop novel CD3 bispecific antibodies
Joint Ventures
Establishing new companies allows us to advance promising medicines discovered and developed by our teams with the managerial, operational and investment expertise of our strategic partners.
-
Magnolia Neurosciences
Launched with Accelerator Life Sciences Partners to develop neuroprotective medicines based on IACS and NDC discoveries
-
Navire Pharma
Launched with BridgeBio Pharma to develop novel small-molecule inhibitors of a tyrosine-protein phosphatase SHP2
-
Vescor
Launched with Deerfield Management to discover and develop autophagy targeted therapeutics for cancer treatment
Licensing Agreements
We have licensed novel therapeutics discovered within our platforms to companies committed to advancing these medicines toward patients in need, often collaborating for ongoing development and early-stage clinical trials.